Commitments and Contingencies |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Commitments and Contingencies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| COMMITMENTS AND CONTINGENCIES | NOTE 9 - COMMITMENTS AND CONTINGENCIES:
On September 23, 2024, the Subsidiary entered into a Clinical Research Organization Services Agreement with a third party to retain it as a clinical research organization (the “CRO”). The services covered by the agreement include strategic planning, expert consultation, data processing, regulatory, clerical, project management and other research and development services requested by the Company in connection with its Phase 3 clinical trial. As consideration for these services, the Company is obligated to pay the CRO an aggregate amount of up to $11,577 over the term of the engagement, payable upon the achievement of specified milestones, of which $54 was recognized in research and development expenses during the nine months ended September 30, 2026.
The Company’s obligations under the Clinical Research Organization Services Agreement remain in effect notwithstanding the Lifeward transaction. However, in light of the change in the planned clinical protocol from a Phase 3 trial to a Phase 2 trial , the Company is engaged in discussions with the CRO to revise the scope of services and reduce the overall cost of the agreement.
The Company has various operating leases for office space and vehicles that expire through 2032.
On August 1, 2026, the Company extended the lease of the second floor of its offices in Israel from January 31, 2027 to January 31, 2032. As a result, the Company recorded an increase of approximately NIS 2,497 thousand ($817) in both the operating right-of-use asset and the operating lease liability.
Below is a summary of the Company’s operating right-of-use assets and operating lease liabilities as of September 30, 2026 and December 31, 2025:
Lease payments for the Company’s right-of-use assets over the remaining lease periods as of September 30, 2026 and December 31, 2025 are as follows:
Future lease payments were discounted by 6%-7% and 3%-7% interest rates as of September 30, 2026 and December 31, 2025, respectively.
As described in Note 4, on December 29, 2025, the Company committed to invest NIS 7,000 thousands ($2,185) as a limited partner in Ruby Sapphire II. As of September 30, 2026, the Company had funded NIS 1,556 thousands ($499) under this commitment, and the remaining unfunded commitment amounted to approximately NIS 5,444 thousands ($1,777).
As described in Note 1, under the Lifeward Notes Purchase Agreement, Lifeward has the right to require the Company to fund Additional Notes in an aggregate principal amount of $9,000, together with the Additional Note Warrants, upon the occurrence of certain conditions. As of September 30, 2026, none of these conditions had been satisfied and the Additional Notes had not been funded. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||